Renal impairment and Amphotericin B formulations in patients with invasive fungal infections

Medical Mycology

Volumn 46, Issue 2, 2008, Pages 97-112

  Saliba, Faouzi ^a   Dupont, Bertrand ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Amphotericin B; Amphotericin B lipid complex (ABLC); Colloidal dispersion of AmB (ABCD); Liposomal amphotericin B (L AmB); Renal failure

Indexed keywords

ACICLOVIR; ADEFOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CARBOPLATIN; CIDOFOVIR; CISPLATIN; COLISTIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; GENTAMICIN; IFOSFAMIDE; LOMUSTINE; NETILMICIN; STREPTOMYCIN; TACROLIMUS; TEICOPLANIN; TENOFOVIR; TOBRAMYCIN; UNINDEXED DRUG; VALACICLOVIR; VANCOMYCIN;

CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DIALYSIS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HUMAN; HYPOKALEMIA; INVASIVE CANDIDIASIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MEDICAL LITERATURE; NEPHROTOXICITY; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT DURATION;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; HUMANS; KIDNEY FAILURE; MYCOSES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 40649108887     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701730469     Document Type: Review

References (93)

1. Kleinberg, M. (2005) Aspergillosis in the CLEAR outcomes trial: Working toward a real-world clinical perspective. Med Mycol, 43, p. S289.
2. Brown, JM. (2004) Fungal infections in bone marrow transplant patients. Curr Opin Infect Dis, 17, pp. 347-352.
3. Marr, KA, Carter, RA, Crippa, F., Wald, A. and Corey, L. (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis, 34, pp. 909-917.
4. Morgan, J., Wannemuehler, KA and Marr, KA (2005) Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol, 43, p. S49.
5. O'Brien, SN, Blijlevens, NM, Mahfouz, TH and Anaissie, EJ (2003) Infections in patients with hematological cancer: Recent developments. Hematology. Am Soc Hematol Educ Prog, pp. 438-472.
6. Singh, N., Wagener, MM, Marino, IR and Gayowski, T. (2002) Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices. Transplantation, 73, pp. 63-67.
7. Upton, A. and Marr, KA. (2006) Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep, 8, pp. 434-441.
8. Abosaif, NY, Tolba, YA, Heap, M., Russell, J. and Nahas, AM. El (2005) The outcome of acute renal failure in the intensive care unit according to RIFLE: Model application, sensitivity, and predictability. Am J Kidney Dis, 46, pp. 1038-1048.
9. Brivet, FG, Kleinknecht, DJ, Loirat, P. and Landais, PJ. (1996) Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med, 24, pp. 192-198.
10. Levy, EM, Viscoli, CM and Horwitz, RI. (1996) The effect of acute renal failure on mortality. A cohort analysis. JAMA, 275, pp. 1489-1494.
11. Liano, F. and Pascual, J. (1998) Outcomes in acute renal failure. Semin Nephrol, 18, pp. 541-550.
12. Chertow, GM, Levy, EM, Hammermeister, KE, Grover, F. and Daley, J. (1998) Independent association between acute renal failure and mortality following cardiac surgery. JAMA, 104, pp. 343-348.
13. Metnitz, PG, Krenn, CG and Steltzer, H. (2002) Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med, 30, pp. 2051-2058.
14. Cheyron, D Du, Bouchet, B., Parienti, JJ, Ramakers, M. and Charbonneau, P. (2005) The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med, 31, pp. 1693-1699.
15. Sabra, R. and Branch, RA. (1990) Amphotericin B nephrotoxicity. Drug Saf, 5, pp. 94-108.
16. Rapp, RP, Gubbins, PO and Evans, ME. (1997) Amphotericin B lipid complex. Ann Pharmacother, 31, pp. 1174-1186.
17. Mehta, J. (1997) Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?. Leuk Res, 21, pp. 183-188.
18. Hiemenz, JW and Walsh, TJ. (1998) Lipid formulations of amphotericin B. J Liposome Res, 8, pp. 443-467.
19. Tiphine, M., Letscher-Bru, V. and Herbrecht, R. (1999) Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis, 1, pp. 273-283.
20. Dix, SP and Andriole, VT. (2000) Lipid formulations of amphotericin B. Curr Clin Top Infect Dis, 20, pp. 1-23.
21. De Mendonca, A., Vincent, JL and Suter, PM (2000) Acute renal failure in the ICU: Risk factors and outcome evaluation by SOFA score. Intensive Care Med, 26, pp. 915-921.
22. Consentino, F., Chaff, C. and Piedmonte, M. (1994) Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant, 9, pp. 179-182.
23. Uchino, S., Kellum, JA and Bellomo, R. (2005) Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA, 294, pp. 813-818.
24. Ympa, YP, Sakr, Y., Reinhart, K. and Vincent, JL. (2005) Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med, 118, pp. 827-832.
25. Wyatt, CM and Arons, RR. (2004) The burden of acute renal failure in nonrenal solid organ transplantation. Transplantation, 78, pp. 1351-1355.
26. Ojo, AO, Held, PJ and Port, FK (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 349, pp. 931-940.
27. Miralbell, R., Sancho, G. and Bieri, S. (2004) Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: A prospective assessment. Int J Radiat Oncol Biol Phys, 58, pp. 809-816.
28. Gruss, E., Bernis, C. and Tomas, JF (1995) Acute renal failure in patients following bone marrow transplantation: Prevalence, risk factors and outcome. Am J Nephrol, 15, pp. 473-479.
29. Letourneau, I., Dorval, M. and Belanger, R. (2002) Acute renal failure in bone marrow transplant patients admitted to the intensive care unit. Nephron, 90, pp. 408-412.
30. Holthe, JE Kist-van, Goedvolk, CA and Brand, R. (2002) Prospective study of renal insufficiency after bone marrow transplantation. Pediatr Nephrol, 17, pp. 1032-1037.
31. Van Why, SK, Friedman, AL, Wei, LJ and Hong, R. (1991) Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant, 7, pp. 383-388.
32. Ankersmit, HJ, Deicher, R. and Moser, B. (2001) Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol, 125, pp. 142-148.
33. Fortun, JP, Martin-Davila, S. and Moreno, E. (2002) Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplant, 8, pp. 1065-1070.
34. Singh, N. and Paterson, DL. (2005) Aspergillus infections in transplant recipients. Clin Microbiol Rev, 18, pp. 44-69.
35. Paphitou, NI, Ostrosky-Zeichner, L. and Rex, JH. (2005) Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: Approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol, 43, pp. 235-243.
36. Stevens, LA and Levey, AS. (2005) Measurement of kidney function. Med Clin North Am, 89, pp. 457-473.
37. Erley, CM, Bader, BD and Berger, ED (2001) Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med, 29, pp. 1544-1550.
38. Wright, JG, Boddy, AV and Highley, M. (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer, 84, pp. 452-459.
39. Herget-Rosenthal, S., Marggraf, G. and Husing, J. (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int, 66, pp. 1115-1122.
40. Mendelssohn, DC, Barrett, BJ and Brownscombe, LM (1999) Elevated levels of serum creatinine: Recommendations for management and referral. CMAJ, 161, pp. 413-417.
41. Gault, MH, Longerich, LL, Harnett, JD and Wesolowski, C. (1992) Predicting glomerular function from adjusted serum creatinine. Nephron, 62, pp. 249-256.
42. Levey, AS, Bosch, JP and Lewis, JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 130, pp. 461-470.
43. Poggio, ED, Nef, PC and Wang, X. (2005) Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis, 46, pp. 242-252.
44. Poggio, ED, Wang, X. and Weinstein, DM (2006) Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant, 6, pp. 100-108.
45. Walsh, TJ, Hiemenz, JW and Seibel, NL (1998) Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis, 26, pp. 1383-1396.
46. Subira, M., Martino, R., Gomez, L., Marti, JM, Estany, C. and Sierra, J. (2004) Low-dose amphotericin B lipid complex versus conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur J Haematol, 72, pp. 342-347.
47. Bates, DW, Su, L. and Yu, DT (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis, 32, pp. 686-693.
48. Bellomo, R., Ronco, C., Kellum, JA, Mehta, RL and Palevsky, P. (2004) Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care, 8, p. R204.
49. Esson, ML and Schrier, RW. (2002) Diagnosis and treatment of acute tubular necrosis. Ann Intern Med, 137, pp. 744-752.
50. Kaloyanides, GJ. (1994) Antibiotic-related nephrotoxicity. Nephrol Dial Transplant, 9, pp. 130-134.
51. Gubbins, PO, Penzak, SR, Polston, S., McConnell, SA and Anaissie, E. (2002) Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy, 22, pp. 961-971.
52. Alexander, BD and Wingard, JR. (2005) Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis, 40, p. S414.
53. Sabra, R., Takahashi, K., Branch, RA and Badr, KF. (1990) Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: A micropuncture study. J Pharmacol Exp Ther, 253, pp. 34-37.
54. Walker, RJ and Duggin, GG. (1988) Drug nephrotoxicity. Annu Rev Pharmacol Toxicol, 28, pp. 331-345.
55. Ng, AW, Wasan, KM and Lopez-Berestein, G. (2003) Development of liposomal polyene antibiotics: An historical perspective. J Pharm Pharm Sci, 6, pp. 67-83.
56. Fanos, V. and Cataldi, L. (2000) Amphotericin B-induced nephrotoxicity: a review. J Chemother, 12, pp. 463-470.
57. Gallis, HA, Drew, RH and Pickard, WW. (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis, 12, pp. 308-329.
58. Boswell, GW, Bekersky, I., Buell, D., Hiles, R. and Walsh, TJ. (1998) Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother, 42, pp. 263-268.
59. Wong-Beringer, A., Jacobs, RA and Guglielmo, BJ. (1998) Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis, 27, pp. 603-618.
60. Williams, P., Waskin, H., Bolcsak, L. and Swenson, C. (1999) Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection. Transplantation, 67, p. S93.
61. Barrett, JP, Vardulaki, KA and Conlon, C. (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther, 25, pp. 1295-1320.
62. Anaissie, EJ, White, M. and Uzun, O. (1995) Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: A prospective, randomized, multicenter trial [abstract LM21]. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 330. San Francisco, CA
63. Luke, RG and Boyle, JA. (1998) Renal effects of amphotericin B lipid complex. Am J Kidney Dis, 31, pp. 780-785.
64. Sharkey, PK, Graybill, JR and Johnson, ES (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis, 22, pp. 315-321.
65. Miller, CB, Waller, EK and Klingemann, HG (2004) Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant, 33, pp. 543-548.
66. Macaulay, SS, Martin, JE and Zarnke, KB. (2002) Amphotericin B for the treatment of systemic fungal infections: Meta-analysis of conventional versus lipid formulations [abstract M-888]. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 393. American Society for Microbiology, (San Diego, CA). Washington, DC
67. Martino, R. (2004) Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): A review of the literature. Curr Med Res Opin, 20, pp. 485-504.
68. Walsh, TJ, Finberg, RW and Arndt, C. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med, 340, pp. 764-771.
69. Prentice, HG, Hann, IM and Herbrecht, R. (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol, 98, pp. 711-718.
70. Leenders, AC, Daenen, S. and Jansen, RL (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol, 103, pp. 205-212.
71. Cagnoni, PJ. (2002) Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother, 49, pp. 81-86.
72. White, MH, Anaissie, EJ and Kusne, S. (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis, 24, pp. 635-642.
73. White, MH, Bowden, RA and Sandler, ES (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis, 27, pp. 296-302.
74. Bowden, R., Chandrasekar, P. and White, MH (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis, 35, pp. 359-366.
75. Walsh, TJ, Pappas, P. and Winston, DJ (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 346, pp. 225-234.
76. Walsh, TJ, Teppler, H. and Donowitz, GR (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med, 351, pp. 1391-1402.
77. Cornely, OA, Maertens, JA and Bresnik, M. (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis, 44, pp. 1289-1297.
78. Wingard, JR, White, MH and Anaissie, E. (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis, 31, pp. 1155-1163.
79. Frothingham, R. (2001) Mortality rates in comparative trials of formulations of amphotericin B. Clin Infect Dis, 33, pp. 582-583.
80. Wingard, JR. (2002) Lipid formulations of amphotericins: Are you a lumper or a splitter?. Clin Infect Dis, 35, pp. 891-895.
81. Imhof, A., Walter, RB and Schaffner, A. (2003) Continuous infusion of escalating doses of amphotericin B deoxycholate: An open label observational study. Clin Infect Dis, 36, pp. 943-951.
82. Pappas, PG. (2005) Amphotericin B lipid complex in the treatment of invasive fungal infections: Results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis, 40, p. S379.
83. Chandrasekar, PH and Ito, JI. (2005) Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis, 40, p. S392.
84. Ito, JI and Hooshmand-Rad, R. (2005) Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis, 40, p. S384.
85. Baddour, LM, Perfect, JR and Ostrosky-Zeichner, L. (2005) Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis, 40, p. S409.
86. Saliba, F., Cheron, N. and Ichaï, P. (2006) A prospective French national survey to assess renal safety of amphotericin B lipid complex and liposomal amphotericin B. Int J Infect Dis, 10, p. S68.
87. Fleming, RV, Kantarjian, HM and Husni, R. (2001) Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma, 40, pp. 511-520.
88. Sastre, JB Lopez, Cotallo, GD Coto and Fernandez, CB. (2003) Neonatal invasive candidiasis: A prospective multicenter study of 118 cases. Am J Perinatol, 20, pp. 153-163.
89. Clark, AD, McKendrick, S., Tansey, PJ, Franklin, IM and Chopra, R. (1998) A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol, 103, pp. 198-204.
90. McKechnie, M., Rotstein, C. and McTaggart, B. (2003) A multi-center, retrospective comparison of the nephrotoxic effects of amphotericin B lipid complex and liposomal amphotericin B. Program and Abstracts of the 13th Focus on Fungal Infections Meeting, p. 48. Chicago, IL
91. McTaggart, B., McKechnie, M., Gin, A., Bombassaro, A., Lui, E. and Carle, S. (2003) Comparative nephrotoxic effects of amphotericin B lipid complex and liposomal amphotericin B in patients with hematological malignancy [abstract M-965]. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 447. San Francisco, CA
92. Couch, K., Chan, S., Cincotta, E., Piper, JP and Forrest, G. (2003) Comparative nephrotoxicity, adverse events, and clinical outcomes of lipid-associated amphotericin B products. Program and Abstracts of the 13th Focus on Fungal Infections Meeting, p. A47. Chicago, IL
93. Cannon, JP, Garey, KW and Danziger, LH. (2001) A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy, 21, pp. 1107-1114.